Rhythm Pharmaceuticals Inc. (RYTM)
Rhythm Pharmaceuticals, Inc. (RYTM) Discusses Positive Interim Results from Phase 2 Setmelanotide Trial in Prader-Willi Syndrome Transcript
Rhythm Pharmaceuticals, Inc. (RYTM) Discusses Positive Interim Results from Phase 2 Setmelanotide Trial in Prader-Willi Syndrome Transcript
Rhythm Pharmaceuticals, Inc. (RYTM) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Rhythm Pharmaceuticals, Inc. (RYTM) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Rhythm Pharmaceuticals, Inc. (RYTM) Q1 2026 Earnings Call Transcript
Rhythm Pharmaceuticals, Inc. (RYTM) Q1 2026 Earnings Call Transcript
Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q1 Loss, Tops Revenue Estimates
Rhythm Pharmaceuticals, Inc. (RYTM) came out with a quarterly loss of $0.83 per share versus the Zacks Consensus Estimate of a loss of $0.86. This compares to a loss of $0.81 per share a year ago.
Analysts Estimate Rhythm Pharmaceuticals, Inc. (RYTM) to Report a Decline in Earnings: What to Look Out for
Rhythm Pharmaceuticals (RYTM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Strength Seen in Rhythm Pharmaceuticals (RYTM): Can Its 12.6% Jump Turn into More Strength?
Rhythm Pharmaceuticals (RYTM) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Rhythm Pharmaceuticals, Inc. (RYTM) Discusses FDA Approval of IMCIVREE for Acquired Hypothalamic Obesity Transcript
Rhythm Pharmaceuticals, Inc. (RYTM) Discusses FDA Approval of IMCIVREE for Acquired Hypothalamic Obesity Transcript
Rhythm Pharmaceuticals Q4 Beat Sets Stage For March 20th PDUFA Decision
Rhythm Pharmaceuticals delivered strong FY25 revenue growth, driven by global demand for IMCIVREE (setmelanotide), reaching $194.8 million, up 50% year-over-year. RYTM's upcoming March 20th FDA PDUFA decision for setmelanotide in acquired hypothalamic obesity could expand the addressable market to 25,000–28,000 patients globally. Positive Phase 3 TRANSCEND data showed a -16.4% mean BMI reduction for setmelanotide, supporting its potential as the first targeted therapy for acquired hypothalamic obesity.
Cinctive Capital Management LP Sells 35,781 Shares of Rhythm Pharmaceuticals, Inc. $RYTM
Cinctive Capital Management LP decreased its holdings in Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM) by 50.4% in the undefined quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 35,156 shares of the company's stock after selling 35,781 shares during the quarter. Cinctive Capital Management LP owned
Rhythm Pharmaceuticals, Inc. (RYTM) Q4 2025 Earnings Call Transcript
Rhythm Pharmaceuticals, Inc. (RYTM) Q4 2025 Earnings Call Transcript
Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q4 Loss, Beats Revenue Estimates
Rhythm Pharmaceuticals, Inc. (RYTM) came out with a quarterly loss of $0.73 per share versus the Zacks Consensus Estimate of a loss of $0.79. This compares to a loss of $0.72 per share a year ago.
Rhythm Pharmaceuticals, Inc. (RYTM) Expected to Beat Earnings Estimates: Should You Buy?
Rhythm Pharmaceuticals (RYTM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
